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Abstract  
Background. Sexual dysfunctions (SD) are frequent in schizophrenia (SZ) and 
associated with treatment withdrawal, however they remain under-explored and 
under-treated. To date, most of the studies have focused on SD as antipsychotics’ side 
effects in therapeutic trials.  
Aims. The objectives of the present study were to determine the SD prevalence in 
stabilized SZ outpatients and their clinical, pharmacological and biological correlates. 
Method. 237 participants (61.2% men) were consecutively included and received a 
thorough 2 days- clinical assessment including the self-reported Sexual Functioning 
Questionnaire (SFQ). SD was defined by a SFQ score ≥8. 
Results. 237 subjects were recruited in the FACE-SZ cohort, 41% of them reported 
sexual dysfunctions. In multivariate analyses, SD have been associated with current 
major depressive disorder (adjusted odd ratio aOR=2.29[1.08-4.85],p=0.03), 
anticholinergic prescription (aOR=2.65, p=0.02) and chronic low-grade inflammation 
(aOR=2.09,p=0.03) independently of age, gender, current cannabis use disorder and 
olanzapine prescription. No antipsychotic has been associated with increased or 
decreased SD rate. 
Conclusions. SD are frequent in SZ subjects. Major depression, anticholinergic 
prescription and chronic low-grade peripheral inflammation may be the three targets 
of interest for addressing this specific issue. 
Declaration of interest. None. 
 
Keywords: sexual dysfunctions; schizophrenia; antipsychotics; major depression; 
inflammation 
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Introduction 
 
Sexual dysfunctions (SD) are defined by the inability of a person to have 
one or all stages of sexual activity including desire, excitement, 
erection/ejaculation for men, vaginal lubrification for women and orgasm. SD 
are frequently reported by patients treated by psychotropic drugs, however they 
have remained underestimated and undertreated for decades.  
Subjects with schizophrenia (SZ) have a specific increased risk of SD 
compared to other psychiatric patients due to antipsychotic consumption that may 
induce hyperprolactinemia. The current international recommendations in case of 
antipsychotic-induced SD are (i) antipsychotic dose decrease, (ii) change to a 
prolactin-sparing antipsychotic, (iii) adding aripiprazole and (iv) phosphodiesterase 
inhibitors (Stroup and Gray, 2018). The authors of these recommendations stipulated 
that the evidence for specific symptom treatments (other than phosphodiesterase 
inhibitors for erectile dysfunction) was lacking (Stroup and Gray, 2018).  
However, SD may not always be due to antipsychotic drug consumption. SZ 
patients are exposed to other SD risk factors that have been identified in non-SZ 
populations, including other psychotropic drugs consumption (especially 
antidepressants, benzodiazepine and anticholinergics), being single, major depression, 
metabolic syndrome, tobacco smoking and chronic peripheral inflammation (G. Fond 
et al., 2018; Godin et al., 2015, 2018; Martín et al., 2018). In summary, there is a lack 
of knowledge on SD in real-world SZ outpatients and on which factors may be 
associated to increased SD. 
The objectives of the present study were to determine the prevalence of sexual 
dysfunctions in the stabilized real-world SZ outpatients of the FACE-SZ national 
cohort and their clinical, pharmacological and biological correlates. 
 
 
Population and methods 
 
The FACE-SZ cohort has been extensively described in previous studies 
(Schürhoff et al., 2018, 2015). The details of the FACE-SZ cohort (study 
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population, diagnosis process, collected data, ethical concerns) are provided in 
supplementary material (Annex 1).  
 
SD definition 
Subjects completed the Sexual Functioning Questionnaire (SFQ), a self 
report structured instrument that has been previously validated in patients with 
psychotic disorders (Smith et al., 2002). The SFQ includes subscales assessing 
libido, physical arousal, erectile function, orgasm and ejaculatory function. Some 
items are reversed. The score is +1 if the patient has answered “yes” to an item 
(presence of sexual dysfunction), or “no” to a reversed item (absence of normal 
sexual function). Higher scores indicate greater impairment, and a total SFQ 
score ≥ 8 is the cut-off indicating sexual dysfunction. 
 
 Sociodemographic, clinical, pharmacological and biological variables 
The clinical scales and metabolic data has been previously comprehensively 
described (Schürhoff et al., 2015) and are available in supplementary material. As the 
clinical evaluation and the biological analyses were separated in time and location, the 
clinical evaluation and the biological analyses were both blinded. Depressive 
symptoms were evaluated using the Calgary Depression Rating Scale for 
Schizophrenia (CDRS (Addington et al., 1992; Lançon et al., 2000)).  Chronic low-
grade peripheral inflammation was defined by a high sensitivity C-reactive 
protein (hs-CRP) ≥3 mg/L (Fond et al., 2016) and was measured with an assay 
using nephelometry (Dade Behring) blinded to schizophrenia status.   
 
Statistical analysis 
Socio-demographics, clinical characteristics, addictive behaviour, treatments, 
biological variables are presented using measures of means and dispersion 
(standard deviation) for continuous data and frequency distribution for 
categorical variables. The data was examined for normal distribution with the 
Shapiro-Wilk test and for homogeneity of variance with the Levene test. 
Comparisons between respectively SD and non-SD subjects regarding 
demographic, clinical, pharmacological and biological variables were performed 
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using the chi-square test for categorical variables. Continuous variables were 
analysed with Student t-tests for normally distributed data and in case of 
normality violation, additional Mann-Whitney tests were performed to confirm 
the result.  
Variables with P values < 0.20 in univariate analyses were included in the 
multivariate analyses (table 2 (whole sample): current cannabis use disorder, 
major depressive disorder, anticholinergics, olanzapine, peripheral 
inflammation, table 3 (men): age, education level, current cannabis use disorder, 
major depressive disorder, first generation antipsychotics, quetiapine, chronic 
peripheral inflammation; table 4 (women): age, education level, major 
depressive disorder, anticholinergics, chronic peripheral inflammation). Age and 
gender were forced in the first model (whole sample) (table 2). The final models 
included odds ratios and 95 % confidence intervals. This study was a 
confirmatory analysis. No correction for multiple testing has therefore been 
carried out, which is consistent with recommendations (Bender and Lange, 
2001). Analyses were conducted using SPSS 17.0 software (SPSS Inc., Chicago, 
IL). All statistical tests were two-tailed, with α level set at 0.05. 
 
Results 
237 subjects (145 men and 92 women) were included in the present study. 
Overall, 96 (40.5%) reported SD (63 (43.4% men and 33 (34.4%) women with no 
difference between genders (p=0.25)). 13 subjects were diagnosed with sleep apnea, 
none of them reported SD. None of the participants reported history of cardiovascular 
or neurological events (including myocardial infarction, stroke or meningitis), 
sexually transmitted chronic viral infection (including B and C hepatitis or HIV), 
addiction to heroin or to opioids or took substitute treatment or phosphodiesterase 
inhibitors. 
The frequency of responses for each SFQ item is described in table 1. Only 
42.6% of the participants reported a sexual activity during the last month. 19.8% 
reported a total absence of sexual desire, 29.1% difficulties in reaching sexual arousal 
and 13.1% an absence of orgasm during the last month. 42.2% reported reaching 
sexual arousal without physical reaction. Almost 10% of the men reported a total 
absence of erection during the last month.  
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The factors associated with SD are presented in table 2 (whole sample), 3 
(men) and 4 (women). In multivariate analyses, SD have been associated with current 
major depressive disorder (adjusted odd ratio aOR=2.29[1.08-4.85], p=0.03), 
anticholinergic prescription (aOR=2.65[1.14-6.14], p=0.02) and chronic low-grade 
inflammation (aOR=2.09[1.08-4.06],p=0.03) independently of age, gender, current 
cannabis use disorder and olanzapine prescription. No other psychotropic drug 
(especially antipsychotics and antidepressants) has been associated with increased or 
decreased SD rate. No dose-effect has been found for any antipsychotic (data not 
shown, all p>0.05). In men, SD were associated with older age (aOR=1.07[1.01-
1.14], p=0.02), lower education level (aOR=0.74[0.61-0.89], p<0.001), major 
depressive disorder (aOR=2.99[1.06-8.49], p=0.04) independently of first-generation 
antipsychotic prescription, quetiapine prescription and peripheral inflammation. In 
women, SD were associated with younger age (aOR=0.93[0.87-0.99],p=0.04) and 
anticholinergic prescription (aOR=5.87[1.09-31.47],p=0.04) independently of 
education level, major depressive disorder and peripheral inflammation.  
Major depressive disorder was more specifically associated with increased 
arousal difficulties (63.0 vs. 30.1%, p=0.001), incomplete erections (28.3 vs.12.8%, 
p=0.02), important delay between orgasm and ejaculation (57.7 vs. 33.6%, p=0.02), 
and orgasm difficulties (61.5 vs. 38.1% vs. p=0.03). Peripheral inflammation was 
associated with increased absence of erection and absence of full erection in men 
(27.8 vs. 13.0% vs. p=0.04 (item 12) and 40.5 vs. 20.6% (item 15)), with rare 
erections (43.2 vs. 20.6%, p=0.08) (item 16)), with difficulties in reaching full 
erection when desired (62.2 vs. 34.7%, p=0.004), with absence of orgasm in men and 
women (24.3 vs. 9.0%, p=0.02). Anticholinergic prescription was associated with 
absence of sexual thought (28.6 vs. 12.4%, p=0.02) and decreased sexual attraction 
(35.7 vs. 11.9%, p=0.002). 
 
Discussion 
 
The present findings may be summarized as follows: in a non-selected sample 
of SZ outpatients, almost 41% reported SD that were independently associated with 
major depressive disorder (but not antidepressant consumption), chronic low-grade 
peripheral inflammation and anticholinergic consumption. Anticholinergic was 
specifically associated with SD in women, while major depression was specifically 
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associated with SD in men. Age was found to have a small but contrary effect in men 
and women. Major depression was found to be associated with arousal, erection, 
ejaculation and orgasm issues, while peripheral inflammation was associated with 
erection and orgasm issues and anticholinergics with sexual desire issues.  
The first result of the present study is that 41% of stabilized SZ outpatients 
report SD, which is high compared to the general population but lower compared to 
previous studies exploring SD in SZ out or inpatients (beyond 50%) (Fan et al., 2007; 
Howes et al., 2007). The observational studies using the SFQ questionnaire are 
scarce, this questionnaire having been mostly used in controlled trials to measure the 
antipsychotics sexual side effects. This prevalence is also similar to those found in 
older non-SZ populations. This is consistent with previous FACE-SZ analyses 
suggesting accelerated aging processes in SZ subjects (and more specifically aging 
related to chronic peripheral inflammation, the so-called “inflammaging”) (Bulzacka 
et al., 2016). Comparing this rate to other SZ populations is difficult given the high 
number of confounding factors (including country, age, sex ratio, age at illness onset, 
tool to evaluate SD, treatments, comorbidities, lifestyle). However this high 
prevalence is an alarm call for clinicians to systematically assess SD in SZ 
outpatients. Beyond current recommendations for SD management summarized in the 
rationale of the present study, our findings may yield other strategies for SD 
management in SZ outpatients. 
Altogether, these results suggest that SD may not be only an antipsychotic 
drug-induced issue in SZ outpatients. The absence of association between the classes 
of antipsychotics (first vs. second generation) confirms previous findings suggesting 
adverse effect profiles being specific to each antipsychotic medication and doing not 
neatly fit into first- and second-generation classifications (Stroup and Gray, 2018). It 
should be underlined that no specific antipsychotic has been associated with increased 
or decreased SD in the present sample, especially aripiprazole that is currently 
recommended in case of SD onset (Stroup and Gray, 2018). Long-acting 
antipsychotics administration was also not associated with decreased SD, while it may 
have been suggested that more stable antipsychotic blood dosage may have decreased 
their side effects. 
On the contrary, SD have been associated with chronic peripheral 
inflammation (but not metabolic syndrome that may be a confounding factor). This is 
consistent with previous findings in non-SZ populations with chronic metabolic 
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diseases (Maiorino et al., 2018). More specifically, endothelial inflammation may 
induce a decreased nitric-oxide-mediated relaxation (Santi et al., 2016) that may 
explain the association between peripheral inflammation and decreased erection 
reported in the SZ men in our study. All sex steroid hormones (specifically DHEA, 
DHEAS and testosterone) have shown anti-inflammatory properties and have been 
shown to improve physical well-being, muscle strength and bone density, and reduces 
body fat (Prall and Muehlenbein, 2018; Rutkowski et al., 2014). A bidirectional 
relationship between chronic peripheral inflammation and SD could therefore be 
hypothesized. DHEA has also been shown to improve psychological well-being, 
which may be particularly useful in SZ patients with both SD and major depression. 
Beyond SD, sex steroid hormones have shown multiple potential benefit in SZ 
subjects (for review see (Soria et al., 2018)). Anti-inflammatory strategies have 
shown effectiveness on SZ and depressive symptomatology (Fond et al., 2014), future 
studies should confirm if they may also improve sexual health of SZ patients.  
SD have been associated with major depression in the present study, but not 
with psychotic symptomatology (and especially not with negative symptoms some of 
which being common with depression like anhedonia or avolition). While this mutual 
association of SD and depression was well known in mood disorders and general 
population (Porto, 2014), it has been found for the first time in schizophrenia. Major 
depression has been previously associated with impaired quality of life in 
schizophrenia independently of negative symptoms (Andrianarisoa et al., 2017) and 
remains underdiagnosed and undertreated (Guillaume Fond et al., 2018). The absence 
of association of antidepressants administration with SD may be explained by the 
coprescription of antipsychotics that may erase this association, all patients being 
treated in the present study. The present results therefore suggest that SZ subjects 
with SD should be evaluated for depression and treated if needed, as antidepressants 
have shown effectiveness in major depression in SZ patients (Guillaume Fond et al., 
2018). The present results suggest that this association was found in men but not in 
women. This result should be taken with caution, as only 21 SZ women with major 
depression were included in the study, which may have led to power lack. 
Anticholinergics have been associated with SD, and specifically with 
decreased sexual desire in SZ women in the present study. The sexual side-effects of 
drugs interfering with cholinergic transmission are known for decades (Aldridge, 
1982). Our results are consistent with those of a previous recent study (Rubio-Abadal 
 10 
et al., 2016). SZ women receiving anticholinergics have reported more than 4 times 
higher SD rates in our study, however only 10 SZ women were administered 
anticholinergics, which highlight the need to replicate this finding in a larger sample. 
It seems reasonable to suggest a background regimen modification or an antipsychotic 
dose decrease with anticholinergic drug withdrawal in case of SD, as anticholinergic 
have other side effects including cognitive impairment. 
While more than 50% of SZ subjects are smokers, no association between 
tobacco smoking and SD has been found in the present sample, which is not 
consistent with previous results (Liu-Seifert et al., 2009; Uçok et al., 2007). This may 
be explained by the young middle age of our sample (32 years) while tobacco 
smoking has been associated with SD mostly in populations mean aged >40 years 
(Biebel et al., 2016). However, it seems still reasonable to recommend tobacco 
smoking cessation to all SZ smokers to avoid later SD onset in addition to other 
health outcomes. More than 85% of the SZ patients were single in our study, but this 
has not been found to be associated with increased SD risk contrary to previous 
findings in non-SZ population. The hypothesis of a bilateral relationship between SD 
and singleness in SZ patients is therefore not validated in our sample. SZ patients 
have been more exposed to childhood trauma compared to the general population, but 
this has not been found as a risk factor for SD in adulthood in our population. 
Education level and age at illness onset, duration of untreated psychosis were also not 
associated with increased SD rates. The increase of SD prevalence with age in men 
has been classically described in both SZ and non-SZ population(Liu-Seifert et al., 
2009), which suggests that our sample may be representative of real-world stabilized 
SZ outpatients. 
Strengths. The multicentric recruitment, the inclusion of never-previously 
explored dimensions in the field of SD (including history of childhood trauma, 
duration of untreated psychosis, age at first thymic episode, chronic peripheral 
inflammation with highly sensitive CRP dosage, hypovitaminosis D, metabolic 
syndrome), the use of a validated self-reported questionnaire to explore SD (and not 
simply asking during a semi-structured interview) and the multivariate analysis 
including confounding factors may be highlighted in the strengths of the present 
study. The metabolic syndrome parameters were measured during evaluation and not 
only reported by questionnaires or interviews. While the sample size may appear as 
limited, the present study is one of the largest study exploring SD in SZ outpatients. 
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The limited number of included patients was due to ethical restriction, the French 
Ethical Committee having classified SD data as sensible research data. The SFQ 
questionnaire was therefore not disseminated to all patients but only in the patients 
participating in the Psy-Coh project follow-up study (Schürhoff et al., 2018). 
Choosing between hetero-reported and self-reported questionnaires is an old an 
unresolved debate (Misdrahi et al., 2016). Each choice has its own advantages and 
disadvantages. In the present study, it was hypothesized that self-questionnaire would 
improve the acceptability to respond to intimate questions. However, almost 20 self-
reported and hetero-rated questionnaires have been developed to explore SD and there 
is no gold standard to date. A systematic review should be carried out as well as 
qualitative studies to determine which tools may be the more appropriate to explore 
SD in SZ subjects. 
Limits. Race/ethnicity has not been reported due to ethical issues. A healthy 
lifestyle based on dietary pattern with high content of whole grain, fruit, nuts and 
seeds, and vegetables and low in sodium and saturated fatty acids plus regular 
physical activity may help to modulate the pro-inflammatory state associated with the 
related burden of sexual dysfunctions (Khoo et al., 2011). Lifestyle (including sleep 
disorders, diet and physical activity) should therefore be included in future studies 
exploring SD in SZ subjects. The number of patient treated by amisulpride (N=11) 
was insufficient to comprehensively explore the potential associations of amisulpride 
with SD. Sexual hormones and prolactinemia dosages have not been carried out as it 
is not recommended in clinical routine practice according to recent recommendations 
(Stroup and Gray, 2018). Like most of the previous studies, all patients were treated 
in the present study; it is therefore difficult to unravel specific factors due to 
schizophrenia itself. Antidepressants were analyzed as a class and subclasses, 
however each antidepressant may have a specific side-effect profile, future studies 
should compare more specifically each antidepressants to determine those at lower 
risk of SD onset in SZ subjects. 
Perspectives. Sildenafil remains an effective option for men with persistent 
erectile dysfunction if the above-mentioned interventions have not been effective 
(Kaminetsky et al., 2017). Exploring the impact of SD (and their improvement) on 
quality of life in SZ real-world outpatients is also a major issue for future studies. 
 
Conclusion 
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Future recommendations for the care of SZ subjects should systematically 
include sexual dysfunctions. This exploration should not be limited to antipsychotic 
drug background regimen modifications. The present findings suggest that treating 
major depression, withdrawing anticholinergics (with decreasing the dose or 
switching the antipsychotic after benefit/risk evaluation, especially in case of 
decreased sexual desire), and improving chronic peripheral inflammation (by 
complementary agents or lifestyle habits modifications), especially in case of erection 
or orgasm issues, may be the three major interventions to address sexual dysfunctions 
in SZ subjects. Sex steroid hormones should also be further explored in case of non-
response to these three strategies.  
 
For sections “conflicts of interest” “acknowledgments” and “contributors” see 
supplementary material Annex 1. 
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